At the 2013 St Gallen International Breast Cancer Conference, an expert panel suggested that indications for adjuvant chemotherapy in early-stage breast cancer included triple-negative breast cancer, human epidermal growth factor receptor 2 (HER2)-positive disease, low hormone receptor status, high Ki-67 status, histologic grade 3 tumors, high 21-gene recurrence score, high-risk 70-gene signature, and the involvement of 3 or more lymph nodes (Table 2). Here, ERBB2 is linked to breast carcinoma.